Company: TVRD
Filing Date: 2025-02-14
Form Type: S-4/A
Source: 0001104659-25-013053
Chunk: 592

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: S-4/A
Chunk 592
---
 (used in) Cara’s operating, investing and financing activities for the nine months ended September 30, 2024 and 2023:

| ​                                                                     
 ​                                                                     
 ​                                                                     | ​ 
 ​ 
 ​ | ​ 
 ​ 
 ​ | Nine Months EndedSeptember 30, 
 2024                           
 Dollar amounts in thousands    |   |         |   | ​ | ​ | 2023 |   |         |   | ​ 
 ​ 
 ​ |
|:----------------------------------------------------------------------|:--|:--|:-------------------------------|:--|--------:|:--|:--|:--|:-----|:--|--------:|:--|:--|
| Net cash used in operating activities                                 | ​ | ​ | ​                              | $ | -56,874 | ​ | ​ | ​ | ​    | $ | -74,708 | ​ | ​ |
| Net cash provided by investing activities                             | ​ | ​ | ​                              | ​ |  43,741 | ​ | ​ | ​ | ​    | ​ |  73,666 | ​ | ​ |
| Net cash (used in) provided by financing activities                   | ​ | ​ | ​                              | ​ |  -1,989 | ​ | ​ | ​ | ​    | ​ |   1,676 | ​ | ​ |
| Net (decrease) increase in cash, cash equivalents and restricted cash | ​ | ​ | ​                              | $ | -15,122 | ​ | ​ | ​ | ​    | $ |     634 | ​ | ​ |

Net cash used in operating activities Net cash used in operating activities for the nine months ended September 30, 2024 consisted primarily of a net loss of $63.2 million and a $13.3 million cash outflow from net changes in operating assets and liabilities, partially offset by a $19.6 million cash inflow from net non-cash charges. The change in operating assets and liabilities primarily consisted of a decrease of $19.1 million in accounts payable and accrued expenses primarily due to operating payments made during the period and a $4.3 million cash lease payment

339

TABLE OF CONTENTS

made to assign Cara’s corporate lease to a third party on November 1, 2024, partially offset by a decrease in prepaid expenses of $5.8 million, primarily related to a decrease in prepaid clinical costs, a decrease in accounts receivable, net — related party of $2.3 million